CVS Health (NYSE:CVS) Upgraded at Wall Street Zen

Key Points

• CVS Health was upgraded by Wall Street Zen from hold to buy, adding to generally positive analyst sentiment on the stock.
• Recent analyst activity has been upbeat overall: multiple firms raised price targets, and MarketBeat says CVS now has a Moderate Buy consensus with a target price of $95.92.
• The company also delivered a strong earnings report, beating Q1 estimates on both EPS and revenue and raising its FY 2026 outlook, which helped push the stock higher.

CVS Health (NYSE:CVS - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday.

Other analysts have also recently issued reports about the company. Piper Sandler decreased their price objective on CVS Health from $101.00 to $99.00 and set an "overweight" rating for the company in a research report on Tuesday, March 31st. Truist Financial increased their price objective on CVS Health from $98.00 to $102.00 and gave the stock a "buy" rating in a research report on Thursday. HSBC increased their price objective on CVS Health from $83.00 to $85.00 and gave the stock a "hold" rating in a research report on Tuesday. UBS Group increased their price objective on CVS Health from $97.00 to $100.00 and gave the stock a "buy" rating in a research report on Thursday. Finally, The Goldman Sachs Group increased their price objective on CVS Health from $95.00 to $97.00 and gave the stock a "buy" rating in a research report on Thursday, February 12th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $95.92.

CVS Health Stock Up 3.6%

Shares of NYSE CVS opened at $90.50 on Friday. The stock has a market cap of $115.47 billion, a PE ratio of 39.87, a price-to-earnings-growth ratio of 0.88 and a beta of 0.60. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. CVS Health has a 52-week low of $58.35 and a 52-week high of $90.89. The business has a 50-day moving average price of $76.86 and a 200 day moving average price of $78.03.

CVS Health (NYSE:CVS - Get Free Report) last announced its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion during the quarter, compared to analysts' expectations of $94.99 billion. During the same period in the prior year, the firm earned $2.25 EPS. The business's revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts forecast that CVS Health will post 7.43 earnings per share for the current year.

Institutional Trading of CVS Health

Hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd lifted its holdings in shares of CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock valued at $26,000 after buying an additional 281 shares during the period. Swiss RE Ltd. acquired a new stake in shares of CVS Health in the 4th quarter valued at approximately $26,000. Sankala Group LLC acquired a new stake in shares of CVS Health in the 4th quarter valued at approximately $28,000. Global Trust Asset Management LLC lifted its holdings in shares of CVS Health by 344.8% in the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator's stock valued at $28,000 after buying an additional 300 shares during the period. Finally, Mcguire Capital Advisors Inc. acquired a new stake in shares of CVS Health in the 4th quarter valued at approximately $28,000. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS beat Wall Street expectations on Q1 earnings and revenue, reporting about $2.9 billion in profit, with improved Aetna profitability helping drive the upside. The company also raised its 2026 outlook, which investors are reading as a sign that the turnaround is gaining traction. CVS Raises 2026 Outlook As Shares Jump 9.8%
• Positive Sentiment: Several brokerages lifted price targets on CVS, including UBS to $100, Truist to $102, and Deutsche Bank to $92, reinforcing the view that recent operating improvements could support more upside from here.
• Positive Sentiment: Analysts and media reports highlighted improving Medicare Advantage metrics, better medical benefit ratios, and operational efficiencies, suggesting CVS’s health insurance business is moving back toward its longer-term margin targets.
• Positive Sentiment: Commentary from investors and media noted that CVS’s prescription volume and pharmacy operations remain solid, while biosimilar and AI initiatives may support long-term cost control and affordability efforts.
• Neutral Sentiment: Pieces discussing Jim Cramer’s prior favorable view on CVS and articles questioning whether the stock is still attractive mainly reinforce sentiment around the name, but do not add new fundamental information.
• Negative Sentiment: Some articles pointed to ongoing structural pressure in the PBM business and the risk that temporary insurance profit strength may not fully offset longer-term margin challenges.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.